« Previous | Next » | All Messages |  MIVT Message Board Home | recommend post |  Ignore Poster

MIVT News Investrend Affiliate SISM Research 'Morning Note' Reiterates MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation, Citing Plans To Introduce New Products In Key Global Markets Next Quarter

NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his "Buy/4" Rating and $2.50 12-month Target Valuation for MIV Therapeutics, Inc. (OTCBB: MIVT) in a “Morning Note.”

The full Research Note, including important disclosures and disclaimers, is available at http://www.sism.com and http://www.investrendresearch.com. In it, analyst Schlotter said:

“Last Thursday MIVT announced that Biosync now has a portfolio of seven new CE Mark-certified cardiovascular stents and related products that can be sold in Europe and other key markets around the world. The launch of Biosync products opens the door for MIVT’s HAp-coated DES and other associated interventional cardiology products, once CE Mark-certified.

“Biosync has strong relations in India and around the world with established distribution networks. The angioplasty market in India ($60M) offers huge opportunities for MIVT. Approx. 70,000 angioplasties are performed every year in India, accounting for only 0.007% of the one billion strong ageing populations. MIVT will primarily targeting the DES market outside the U.S. is estimated to reach $4 billion in 2008.”

SISM Research believes that the Biosync acquisition will help the Company in a short time to realize the full potential of its earning power and further drive its valuation. At a market valuation of only $56M the Research Company believes that MIVT is significantly undervalued.

MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage."

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM Research writes, publishes and distributes research coverage on micro- to small-cap public companies trading on the OTC, NASDAQ and AMEX.

This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall and Investext, to Reuters Multex, Knobias and Investrend.

The full report, including important disclosures and disclaimers, is available at http://www.sism.com, http://www.investrendresearch.com, and at the company's InvestorPower Page accessible from http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

Both SISM Research and Investrend Research subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and MIVT's research will be enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).

Anyone interested in receiving alerts regarding MIV Therapeutics research should email contact@investrend.com with "MIVT" in the subject line.

Forward-Looking Statements: Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results.